FILTER
FILTERED INTERVIEW RESULTS
Lesley Millar-Nicholson
DIRECTOR, MIT TECHNOLOGY LICENSING OFFICE
"MIT spins out over 32 startup companies per year approximately, and we have about 358 companies that are still alive, so the ecosystem is functioning well."
Robert E. Landry
EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER, REGENERON
Regeneron explains how its capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process.
Donna LaVoie
PRESIDENT & CEO, LAVOIEHEALTHSCIENCE
LaVoie Health Science explains how the communication requirements for Biotech companies have evolved significantly.
Jeff Reingold
COO, CONTRACT PHARMACAL CORP
Contract Pharmacal Corp explains how it is intends to maintain its organic growth.
Dr. Trevor P. Castor
PRESIDENT & CEO, APHIOS
Aphios explains its developments in Critical Fluid Inactivation, cannabidiol in the area of cancer-induced peripheral neuropathic pain, and combination therapeutics and methods for the treatment of neurodegenerative diseases.
Dr. Josep Bassaganya-Riera
CHAIRMAN, PRESIDENT AND CEO, LANDOS BIOPHARMA
Landos Biopharma is rapidly developing into an integrated biotech company with a powerful R&D engine and a robust commercial arm.
Scott Bluestein
CEO & CIO, HERCULES CAPITAL
Hercules Capital explains why it is well positioned to benefit from a thriving life sciences and technology scene.
James Sapirstein
PRESIDENT & CEO, AZURRX BIOPHARMA
AzurRx Biopharma has benefitted from the availability of financing to expand its pipeline.
William H. Lewis
CHAIR & CEO, INSMED
2020 has been a transformative year for Insmed that is now undertaking three exciting programs for rare and serious diseases.
Christiana Bardon
PORTFOLIO MANAGER, BURRAGE CAPITAL, MANAGING DIRECTOR, ONCOLOGY IMPACT FUND, MPM CAPITAL
Burrage Capital speaks to GBR about the current wave of enthusiasm investors are showing towards biotech.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
